Proxy Results Form 8 K

As disclosed in Item 5.07 below, on August 29, 2024, Benitec Biopharma Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting"). At the Special Meeting, the Company's stockholders approved an amendment (the "Third Plan Amendment") to the Company's 2020 Equity and Incentive Compensation Plan, which was previously approved by the Company's board of directors. A description of the terms of the Third Plan Amendment can be found in Proposal 2 - Approval of Amendment to the 2020 Equity and Incentive Compensation Plan in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the "SEC") on July 29, 2024 and incorporated herein by reference. Such summary is qualified in its entirety by reference to the terms of the Third Plan Amendment, a copy of which is attached hereto as Exhibit 10.1 and is incorporated by reference into this Item 5.02.